European pharma group Mundipharma has struck a deal with Janssen for two primary care diabetes drugs, Invokana and Vokanamet, in selected European countries.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.